Abstract B027: Antitumor effects of the programmed death receptor-1 and the programmed death-ligand 1 blockade in human colorectal carcinoma in a humanized orthotopic mouse model

2019 ◽  
Author(s):  
Li Li ◽  
Xin Zhang ◽  
Grace Maresh ◽  
Linh Hellmers ◽  
Avi Patel ◽  
...  
Keyword(s):  
Colorectal Carcinoma ◽  
Mouse Model ◽  
Death Receptor ◽  
Antitumor Effects ◽  
Orthotopic Mouse Model ◽  
Programmed Death Ligand 1 ◽  
Programmed Death ◽  
Human Colorectal Carcinoma

scholarly journals Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade

RSC Advances ◽  
2019 ◽  
Vol 9 (58) ◽  
pp. 33903-33911 ◽  
Author(s):  
Min Zhang ◽  
Kehai Liu ◽  
Mingfu Wang
Keyword(s):  
Side Effects ◽  
Cancer Immunotherapy ◽  
Response Rate ◽  
Death Receptor ◽  
Programmed Death Ligand 1 ◽  
Programmed Death

The possible reasons that caused low response rate and severe side effects of programmed death receptor 1 (PD-1)/programmed death ligand 1 (PD-L1) blockade therapy and corresponding strategies.

scholarly journals Intermittent hypoxia enhances the tumor programmed death ligand 1 expression in a mouse model of sleep apnea

2019 ◽  
Vol 7 (5) ◽  
pp. 97-97 ◽  
Author(s):  
Mao-Hong Huang ◽  
Xiao-Bin Zhang ◽  
Hui-Ling Wang ◽  
Liu-Xia Li ◽  
Yi-Ming Zeng ◽  
...  
Keyword(s):  
Sleep Apnea ◽  
Mouse Model ◽  
Intermittent Hypoxia ◽  
Programmed Death Ligand 1 ◽  
Programmed Death

scholarly journals Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe?

2016 ◽  
Vol 140 (4) ◽  
pp. 326-331 ◽  
Author(s):  
Keith M. Kerr ◽  
Fred R. Hirsch
Keyword(s):  
Lung Cancer ◽  
Death Receptor ◽  
Cancer Therapeutics ◽  
Predictive Biomarker ◽  
Small Cell ◽  
Small Cell Lung ◽  
Treatment Area ◽  
Programmed Death Ligand 1 ◽  
Programmed Death ◽  
Biomarker Testing

The approval of anti-programmed death receptor (PD)-1 therapies for non–small cell lung cancer has directed the spotlight on programmed death ligand-1 (PD-L1) immunohistochemistry as the latest predictive biomarker potentially required in this disease. Several other drugs in this class will likely be approved in the future and each has been developed with a unique anti–PD-L1 immunohistochemistry test. The prospect of 5 drugs competing in the same treatment area, each possibly requiring PD-L1 immunohistochemistry testing, presents a challenge for pathologists unlike any previously faced. The key issue is whether laboratories will attempt to deliver the trial-validated assays for one or more of these treatments, or introduce instead one or more laboratory developed tests, or attempt to provide a single PD-L1 immunohistochemistry assay for all possible anti–PD-1 and anti–PD-L1 treatments that may be used. This paper discusses some of the issues, challenges, hazards, and possible solutions that have recently emerged in this most complex interface between cancer therapeutics and laboratory biomarker testing.

scholarly journals Nivolumab-induced adrenalitis

2019 ◽  
Vol 12 (11) ◽  
pp. e231829 ◽  
Author(s):  
Iqra Iqbal ◽  
Muhammad Atique Alam Khan ◽  
Waqas Ullah ◽  
Dina Nabwani
Keyword(s):  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Death Receptor ◽  
Small Cell ◽  
Second Line ◽  
Small Cell Lung ◽  
Programmed Death Ligand 1 ◽  
Programmed Death ◽  
Life Threatening ◽  
Line Chemotherapy

Immune checkpoint inhibitors (ICIs) are an evolving class of drugs for the treatment of various cancers; for example, their use is recommended as a second-line chemotherapy for non-small cell lung cancer. With the expanding use of ICIs, we are discovering their unique side effects, called immune-related adverse events (irAEs), which can impair gastrointestinal, hepatic, dermatological, endocrine and other systems. Nivolumab is an ICI that blocks the human programmed death receptor-1 (PD-1) on T cells to prevent the interaction between the receptor, PD-1, and human programmed death ligand-1 expressed on tumour cells. Here, we report a case of a 65-year-old woman with recurrent lung adenocarcinoma who was treated with nivolumab and developed immune-related adrenalitis, which was managed with hydrocortisone and fludrocortisone. This case highlights the importance of understanding the irAEs of ICIs to allow prompt recognition and management of life-threatening complications of the treatment.

Sign in / Sign up

Export Citation Format

Share Document